🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Registry of Endovascular Treatment for Vertebrobasilar Dissecting Aneurysms in China

Recruitingn/aAges 18 Years - 80 YearsAllBeijing Tiantan Hospital
NCT06541106 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The incidence of vertebrobasilar dissecting aneurysms (VBDAs) is about 1/100,000\~1.5/100,000, and it is one of the most important causes of stroke in young and middle-aged people. In recent years, with the development of medical imaging technology, the detection rate of this disease has been increasing year by year. The natural prognosis of VBDAs is complex and varied, with uncertainty: (1) it may have a benign course, and the imaging follow-up may show that the diseased vessels are repaired and improved or remain stable for a long period of time; (2) it may present with ischemic stroke caused by hemodynamic alteration or thromboembolism, which may result in severe neurological impairment; (3) it may occur as a result of rupture of aneurysms leading to subarachnoid hemorrhage, endangering the patient's life; (4) progressive enlargement of VBDAs causing occupying effects, which may be ma

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-80 years old; 2. Patients diagnosis of "unruptured vertebrobasilar dissecting aneurysm". Exclusion Criteria: 1. Patients did not undergo a cranial MRI; 2. Missing critical clinical baseline; 3. Missing pre-treatment imaging; 4. Receiving microsurgery; 5. The combination of other serious diseases during diagnosis will significantly affect the follow-up of patients; 6. CT/MRI shows intracranial hemorrhage or subarachnoid hemorrhage (SWI microbleeds are ignored).
💊

What it tests

  • Multi-disciplinary assessment
📍

Where

1 site
Beijing Tiantan Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy